BioSpace News Archive

Dental professionals have long sought improvements in dental implant bridge stability, longevity, and esthetics.

Orpha Labs AG announced its compassionate use program to make ORL-101 available to physicians providing care for Leukocyte Adhesion Deficiency Type II patients.

ANGLE plc, a world-leading liquid biopsy company, is pleased to announce that the National and Kapodistrian University of Athens has published results of a new study undertaken in non-small cell lung cancer.

Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization of mammalian, microbial and gene therapy biologics, announces its first webinar of the 2021 series: Regulatory Strategies for Gene Therapy Product Development.

Partnership to accelerate CE marking of Avacta’s SARS-CoV-2 rapid antigen test and support COVID-19 testing in low and middle income countries

New solutions enable enhanced delivery, tracking and management of drug safety reporting and medical questions from sites

Anticancer Bioscience, pioneers in synthetic lethal approaches to precision oncology, announced that having successfully closed an additional financing round, raising CNY63m, it has already achieved positive animal data in its small molecule program targeting MYC overexpression.

CareCapital Advisors Limited announces the appointment of Mr. A P A Bindusaran as Executive Director and Head of DSO Clinical and Business Development.

Targeting First-Patient-In for IDE397 Phase 1 study in Q1 2021, as a potential best-in-class MAT2A inhibitor for cancer patients harboring MTAP-deletion, which is prevalent in ~15% of all solid tumors

Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics based on Seneca Valley Virus, announced the expansion of its R&D pipeline with six new armed gene therapy/oncolytic constructs directed against important cancer targets and indications.